GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

The Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity (DH)

Not Applicable

Completed

Conditions: Dentin Sensitivity

Interventions: Other: Stannous fluoride
Other: Sodium monofluorophosphate

First Posted Date: 2016-10-05

Last Posted Date: 2018-08-20

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 205

Registration Number: NCT02924350

Locations: 🇬🇧
GSK Investigational Site, Bristol, United Kingdom

To Investigate the Efficacy of an Occluding Dentifrice in Dentinal Hypersensitivity (DH)

Phase 4

Completed

Conditions: Dentin Sensitivity

Interventions: Other: Stannous fluoride
Other: Sodium monofluorophosphate

First Posted Date: 2016-10-05

Last Posted Date: 2018-10-29

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 197

Registration Number: NCT02923895

Locations: 🇨🇦
GSK Investigational Site, Mississauga, Ontario, Canada

Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks

Phase 3

Completed

Conditions: Rotavirus Vaccines
Infections, Rotavirus

Interventions: Biological: HRV PCV-free liquid vaccine
Biological: Rotarix

First Posted Date: 2016-09-26

Last Posted Date: 2020-07-21

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1612

Registration Number: NCT02914184

Locations: 🇨🇳
GSK Investigational Site, Taoyuan, Taiwan

Evaluation of Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarix (GSK444563) in Healthy Infants

Phase 4

Completed

Conditions: Rotavirus

Interventions: Biological: Squarekids
Biological: Rotarix

First Posted Date: 2016-09-20

Last Posted Date: 2019-11-25

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 292

Registration Number: NCT02907216

Locations: 🇯🇵
GSK Investigational Site, Tokyo, Japan

GSK2982772 Study in Subjects With Ulcerative Colitis

Phase 2

Completed

Conditions: Colitis, Ulcerative

Interventions: Drug: Placebo
Drug: GSK2982772

First Posted Date: 2016-09-16

Last Posted Date: 2020-06-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 36

Registration Number: NCT02903966

Locations: 🇬🇧
GSK Investigational Site, Dudley, United Kingdom

Long-term Persistence of Immunity to Hepatitis B in Adults Vaccinated With GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine (HBV), Engerix-B

Phase 4

Completed

Conditions: Hepatitis B Vaccine

Interventions: Biological: Engerix-B

First Posted Date: 2016-09-15

Last Posted Date: 2020-01-02

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 106

Registration Number: NCT02901951

Locations: 🇨🇦
GSK Investigational Site, Sherbrooke, Quebec, Canada

A PH I Pilot Imaging Study to Evaluate Molecular Imaging Methods in HVs and pSS Pts

Not Applicable

Completed

Conditions: Autoimmune Diseases

Interventions: Radiation: 18F-FDG PET/CT Imaging
Procedure: MRI Imaging with intravenous contrast with gadoterate meglumine
Radiation: 11C-MET PET/CT Imaging
Procedure: Minor Salivary gland (labial) biopsy